High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity

Kidney Int. 2003 Aug;64(2):728-36. doi: 10.1046/j.1523-1755.2003.00125.x.


Background: Iron is essential for the formation of hemoglobin. During long-term treatment with human recombinant erythropoietin (rhEPO), the majority of end-stage renal disease (ESRD) patients will not respond adequately to rhEPO unless substituted with intravenous iron. However, concern exists about possible detrimental effects of parenteral iron on cellular host defense and iron-mediated increments of oxidative stress.

Methods: We analyzed phagocytic functions of polymorphonuclear leukocytes (PMN) isolated from 20 ESRD patients on peritoneal dialysis in response to 300 mg of iron sucrose or placebo administered intravenously over two hours in a randomized, double-blind manner. We evaluated Fc gamma R-dependent phagocytosis and killing (primary outcome variable) of opsonized Escherichia coli, Fc gamma R-dependent oxidative burst capacity, and complement receptor 3 (CR3, Mac1, CD11b/CD18)/tumor necrosis factor alpha (TNFalpha)-mediated release of bactericidal lactoferrin before, during, one hour, and two days after administration.

Results: The absolute count and the percentage of E. coli killed by PMN of iron sucrose-treated peritoneal dialysis patients decreased significantly over time in comparison to placebo-treated patients (F = 3.48, df = 4, P = 0.008; F = 3.99, df = 4, P = 0.006, respectively). All secondary outcome variables were not different between both groups over time.

Conclusions: Killing capacity of PMN isolated from ESRD patients decreases in response to high-dose parenteral iron sucrose, possibly in part explaining reported higher hospitalization rates and lower survival rates of dialysis patients receiving frequent and high-dose parenteral iron.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Anemia / drug therapy*
  • Anemia / immunology
  • Ferric Compounds / administration & dosage*
  • Ferric Compounds / adverse effects*
  • Ferric Oxide, Saccharated
  • Glucaric Acid
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / complications*
  • Kidney Failure, Chronic / therapy
  • Neutrophils / drug effects*
  • Neutrophils / immunology
  • Peritoneal Dialysis
  • Phagocytosis / drug effects
  • Prospective Studies
  • Respiratory Burst / drug effects


  • Ferric Compounds
  • Ferric Oxide, Saccharated
  • Glucaric Acid